Science on a Chip: Lab Platform for ALS Study Lets Researchers Make Muscle Fibers in Gelatin

Herantis Pharma announced that a pipeline therapy known as cerebral dopamine neurotrophic factor (CDNF) has been granted Orphan Drug Status by the U.S. Food and Drug Administration (FDA) to speed its development and testing as a potential treatment for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. Cerebral dopamine neurotrophic factor is a neuroprotective and…

Researchers at the University of Tokyo demonstrated that the FDA-approved anti-epileptic drug perampanel is able to prevent the progression of amyotrophic lateral sclerosis (ALS) and normalize the death of motor neurons in an animal model of the disease. The findings indicate the drug may be a potential candidate for ALS treatment and…

Researchers at the University of California conducted a study on the molecular and genetic characteristics of two identical female twins, one only with amyotrophic lateral sclerosis (ALS), and found that environmental factors may be at the root of genetic modifications that cause the disease. The discovery may be a key to prevention…

Transplanting human stem cells into the spinal cord of people with amyotrophic lateral sclerosis (ALS) may be safely accomplished, according to the results of a Phase 2 clinical trial. The study, led by researchers at the Emory University School of Medicine and the Nell Hodgson Woodruff School of Nursing in…

Measuring copper concentration in the blood may allow for the diagnosis of amyotrophic lateral sclerosis (ALS) before the onset of clinical symptoms, according to new research in mice. The study, developed by researchers at the University of Wollongong in Australia, might provide a new means for ALS diagnosis that does not require disease…

By screening nearly 250 factors in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS), Chinese researchers were able to identify a marker linked to disease severity. The team also found a protein that distinguished ALS from other neurological diseases which, if confirmed in larger studies, could act as a…

An analysis of inflammatory marker levels in blood samples from amyotrophic lateral sclerosis (ALS) patients, improves patient categoration and may help design future ALS clinical trials, according to a new study. The study “Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis,” was published in the journal…